INPP5D and B-cell chronic lymphocytic leukemia: We, therefore, propose transient inhibition of SHIP1 as an unexpected concept for CLL therapy, either alternating with kinase inhibition to potentially enhance the effect of both solo treatments or to treat the rising cases of kinase inhibitor-resistant disease.